Evidence map›Paper›PMID 28116092›Full record

ArticlePharmacology research & perspectives2016

Teleocidin A2 inhibits human proteinase-activated receptor 2 signaling in tumor cells.

Sonja Stahn, Lisa Thelen, Ina-Maria Albrecht, Jens Bitzer, Thomas Henkel, Nicole Elisabeth Teusch

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmacology research & perspectives, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 9 citations in OpenAlex.

  1. Bacterial terpenome.Natural product reports · 2021
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sonja StahnBio-Pharmaceutical Chemistry Faculty of Applied Natural Sciences Cologne University of Applied Sciences Chem Park Leverkusen Leverkusen Germany.
Lisa ThelenBio-Pharmaceutical Chemistry Faculty of Applied Natural Sciences Cologne University of Applied Sciences Chem Park Leverkusen Leverkusen Germany.
Ina-Maria AlbrechtBio-Pharmaceutical Chemistry Faculty of Applied Natural Sciences Cologne University of Applied Sciences Chem Park Leverkusen Leverkusen Germany.
Jens BitzerIMD Natural Solutions GmbH Dortmund Germany.
Thomas HenkelIMD Natural Solutions GmbH Dortmund Germany.
Nicole Elisabeth TeuschBio-Pharmaceutical Chemistry Faculty of Applied Natural Sciences Cologne University of Applied Sciences Chem Park Leverkusen Leverkusen Germany.
TH Köln - University of Applied Sciences · DEKlinikum Leverkusen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhanced expression of the proteinase-activated receptor 2 (PAR2) is linked to cell proliferation and migration in many cancer cell types. The role of PAR2 in cancer progression strongly illustrates the need for PAR2-inhibiting compounds. However, to date, potent and selective PAR2 antagonists have not been reported. The natural product teleocidin A2 was characterized against PAR2-activating peptide SLIGKV-NH

Indexed as

Breast cancermigrationproteinase‐activated receptor 2teleocidin

Identifiers

PMID28116092
PMCPMC5242168
OpenAlexW2473624868

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.